drugset / Trial / NCT02342392

Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

NCT02342392

Phase 2/3 Completed 36 enrolled Universiti Sains Malaysia
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the pterygium vascularity and size before and after intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium excision surgery.

Timeline

Start
2012-09
Primary completion
2014-09
Completion
2014-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranibizumab Monoclonal antibody 0.3 mg Other

Indications